Skip to main content
An official website of the United States government
Español
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

idecabtagene vicleucel

(I-deh-KAB-tuh-jeen vik-LOO-sel)
A treatment used for adults with multiple myeloma that came back or did not get better after treatment with at least two lines of anticancer therapy that included an immunomodulating agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Idecabtagene vicleucel is made using a patient’s T cells (a type of immune system cell). A gene for a special receptor called chimeric antigen receptor (CAR) is added to the T cells in the laboratory. These changed T cells called CAR T cells are grown in large numbers in the laboratory and given to the patient by infusion. Idecabtagene vicleucel binds to a protein called BCMA, which is found on myeloma cells and some types of immune cells. This helps the body’s immune system kill cancer cells. Idecabtagene vicleucel is a type of cellular immunotherapy called CAR T-cell therapy. Also called Abecma.
Search NCI's Dictionary of Cancer Terms